Coya Therapeutics, Inc. (COYA)
(Real Time Quote from BATS)
$6.90 USD
-0.34 (-4.70%)
Updated Jul 30, 2024 12:20 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
COYA 6.90 -0.34(-4.70%)
Will COYA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for COYA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for COYA
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS
Here's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep going
COYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
Other News for COYA
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
Coya Therapeutics expands sponsored research collaboration with HMRI
Eli Lilly And Alzheimer's Disease: The Paucity Of Progress
Analysts Are Bullish on These Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Protagonist Therapeutics (PTGX)
Coya Therapeutics files to sell 603K common shares for holders